CLBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLBT is not a clear buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The business is improving, the latest quarter showed solid growth, and recent news is positive, but the stock is already near resistance and the technical setup is mixed. Wall Street remains constructive, yet price-target cuts show expectations are being tempered. With no strong proprietary buy signal and sentiment not extreme enough to justify an urgent entry, the better call today is to hold and wait for a cleaner setup rather than buy aggressively now.
The trend is moderately constructive but not decisive. CLBT closed at 13.94, above the prior close of 13.81 and just above pivot support at 13.189. MACD histogram is positive and expanding, which supports short-term upside momentum. RSI_6 at 67.7 is elevated but not overbought, suggesting strength without a strong breakout signal. Moving averages are converging, implying the stock is at an inflection point rather than in a strong established trend. Resistance sits nearby at 13.79 and 14.162, so upside may be capped in the short term. The pattern-based expectation is mildly bearish near term, with a 60% chance of weakness over the next day/week/month, which reduces urgency for a new long entry.
["FedRAMP High authorization for the Government Cloud platform, which should strengthen competitive positioning in public safety and federal markets.", "Potential for faster adoption by federal agencies handling digital evidence, including FBI and DEA workflows.", "New technology leadership with Shiven Ramji, which may support product innovation and AI development.", "Latest quarter showed revenue growth of 18.13% YoY and net income growth of 7.68% YoY.", "Gross margin remained very strong at 84.71%, indicating durable software economics.", "Analysts remain broadly positive with Buy ratings despite target reductions."]
["Multiple analysts lowered price targets recently, signaling some moderation in expectations.", "No strong Intellectia proprietary buy signal today: AI Stock Picker is absent and SwingMax has no recent signal.", "Hedge funds and insiders are neutral, so there is no notable accumulation signal from smart-money activity.", "The stock is trading near nearby resistance levels, limiting immediate upside.", "Pattern analysis suggests short-term downside bias in the next day, week, and month.", "High implied volatility means the market already expects movement and enthusiasm is partly priced in."]
Latest reported quarter: 2025/Q4. Revenue increased to 128.821 million, up 18.13% YoY, which is a strong growth rate. Net income rose to 20.748 million, up 7.68% YoY, showing profitability improvement but slower growth than revenue. EPS was 0.08, flat YoY, suggesting earnings expansion is still modest. Gross margin improved to 84.71%, up 1.04 points YoY, which is excellent for a software platform and supports long-term fundamentals.
Wall Street remains positive overall: Needham, TD Cowen, and Lake Street all kept Buy ratings, but each lowered price targets recently, from $24 to $18, $25 to $23, and $23 to $21 respectively. The pros view is that Cellebrite is executing well, delivered solid 4Q25 results, grew ARR by 21% YoY, and has AI as a force multiplier plus a strong FedRAMP-related expansion story. The cons view is that market contraction and more conservative profit assumptions have led analysts to trim targets, showing that expectations are less aggressive than before.
